UTHR – United Therapeutics Corporation
United Therapeutics CorporationUTHR
$477.86Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $21,611,821,056.00
EPSttm : 26.36
United Therapeutics Corporation
$477.86
0.42%$2.01Float Short %
4.16
Margin Of Safety %
6
Put/Call OI Ratio
0.66
EPS Next Q Diff
-0.18
EPS Last/This Y
0.66
EPS This/Next Y
1.49
Price
475.31
Target Price
540.27
Analyst Recom
1.6
Performance Q
4.83
Relative Volume
0.41
Beta
0.86
Ticker: UTHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-13 | UTHR | 476.88 | 0.71 | 1.50 | 33203 |
| 2026-01-14 | UTHR | 475.68 | 0.71 | 5.11 | 33194 |
| 2026-01-15 | UTHR | 471.53 | 0.71 | 0.13 | 33202 |
| 2026-01-16 | UTHR | 464.78 | 0.70 | 0.70 | 33092 |
| 2026-01-20 | UTHR | 467.73 | 0.68 | 0.18 | 21334 |
| 2026-01-21 | UTHR | 469.77 | 0.67 | 0.79 | 21495 |
| 2026-01-22 | UTHR | 471.59 | 0.68 | 1.13 | 21598 |
| 2026-01-23 | UTHR | 468.6 | 0.68 | 3.28 | 21641 |
| 2026-01-26 | UTHR | 473.7 | 0.69 | 0.12 | 21838 |
| 2026-01-27 | UTHR | 476.72 | 0.69 | 0.63 | 21867 |
| 2026-01-28 | UTHR | 467.12 | 0.69 | 0.16 | 21887 |
| 2026-01-29 | UTHR | 467.41 | 0.69 | 0.10 | 21916 |
| 2026-01-30 | UTHR | 469.49 | 0.69 | 1.34 | 21907 |
| 2026-02-02 | UTHR | 474.89 | 0.69 | 0.19 | 22043 |
| 2026-02-03 | UTHR | 478.06 | 0.69 | 0.58 | 22103 |
| 2026-02-05 | UTHR | 478.65 | 0.65 | 0.91 | 28285 |
| 2026-02-09 | UTHR | 472.9 | 0.65 | 0.51 | 28310 |
| 2026-02-10 | UTHR | 473.08 | 0.66 | 1.95 | 27309 |
| 2026-02-11 | UTHR | 475.69 | 0.66 | 0.45 | 27331 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-13 | UTHR | 476.95 | 17.0 | 33.2 | 27.10 |
| 2026-01-14 | UTHR | 475.49 | 17.0 | 50.3 | 27.10 |
| 2026-01-15 | UTHR | 471.54 | 17.0 | 38.1 | 27.10 |
| 2026-01-16 | UTHR | 464.86 | 17.0 | 25.2 | 27.10 |
| 2026-01-20 | UTHR | 468.03 | 17.0 | 70.1 | 27.10 |
| 2026-01-21 | UTHR | 469.63 | 17.0 | 63.4 | 27.10 |
| 2026-01-22 | UTHR | 471.62 | 17.0 | 64.4 | 27.10 |
| 2026-01-23 | UTHR | 468.60 | 17.0 | 42.8 | 27.10 |
| 2026-01-26 | UTHR | 473.36 | 17.0 | 75.7 | 27.10 |
| 2026-01-27 | UTHR | 476.57 | 17.0 | 70.3 | 27.10 |
| 2026-01-28 | UTHR | 467.14 | 17.0 | 14.7 | 27.10 |
| 2026-01-29 | UTHR | 467.52 | 17.0 | 57.3 | 27.10 |
| 2026-01-30 | UTHR | 469.55 | 17.0 | 64.5 | 27.10 |
| 2026-02-02 | UTHR | 475.07 | 17.0 | 80.9 | 27.10 |
| 2026-02-03 | UTHR | 477.97 | 17.0 | 69.2 | 27.10 |
| 2026-02-04 | UTHR | 482.55 | 17.0 | 75.4 | 27.10 |
| 2026-02-05 | UTHR | 478.83 | 17.0 | 40.4 | 27.10 |
| 2026-02-06 | UTHR | 485.44 | 17.0 | 84.6 | 27.10 |
| 2026-02-09 | UTHR | 472.77 | 17.0 | 2.0 | 27.10 |
| 2026-02-10 | UTHR | 473.11 | 17.0 | 56.7 | 27.10 |
| 2026-02-11 | UTHR | 475.31 | 17.0 | 65.4 | 27.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-13 | UTHR | -40.69 | -5.72 | 4.40 |
| 2026-01-14 | UTHR | -40.69 | -5.72 | 4.40 |
| 2026-01-15 | UTHR | -40.63 | -5.72 | 4.40 |
| 2026-01-16 | UTHR | -40.63 | -5.72 | 4.40 |
| 2026-01-20 | UTHR | -40.63 | -5.32 | 4.40 |
| 2026-01-21 | UTHR | -40.63 | -5.32 | 4.40 |
| 2026-01-22 | UTHR | -40.63 | -5.32 | 4.40 |
| 2026-01-23 | UTHR | -40.63 | -5.32 | 4.40 |
| 2026-01-26 | UTHR | -40.38 | -5.32 | 4.40 |
| 2026-01-27 | UTHR | -40.38 | -5.32 | 4.40 |
| 2026-01-28 | UTHR | -41.41 | -5.32 | 4.30 |
| 2026-01-29 | UTHR | -41.41 | -5.32 | 4.30 |
| 2026-01-30 | UTHR | -41.41 | -5.32 | 4.30 |
| 2026-02-02 | UTHR | -41.41 | -3.82 | 4.30 |
| 2026-02-03 | UTHR | -41.92 | -3.82 | 4.30 |
| 2026-02-04 | UTHR | -41.92 | -3.82 | 4.30 |
| 2026-02-05 | UTHR | -42.10 | -3.82 | 4.30 |
| 2026-02-06 | UTHR | -42.10 | -3.82 | 4.30 |
| 2026-02-09 | UTHR | -41.86 | -3.94 | 4.30 |
| 2026-02-10 | UTHR | -42.36 | -3.94 | 4.30 |
| 2026-02-11 | UTHR | -42.36 | -3.94 | 4.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
7.16
Avg. EPS Est. Current Quarter
6.88
Avg. EPS Est. Next Quarter
6.98
Insider Transactions
-42.36
Institutional Transactions
-3.94
Beta
0.86
Average Sales Estimate Current Quarter
817
Average Sales Estimate Next Quarter
819
Fair Value
506.04
Quality Score
100
Growth Score
97
Sentiment Score
61
Actual DrawDown %
8.6
Max Drawdown 5-Year %
-33
Target Price
540.27
P/E
18.03
Forward P/E
15.58
PEG
1.5
P/S
6.55
P/B
3.1
P/Free Cash Flow
18.26
EPS
26.39
Average EPS Est. Cur. Y
27.1
EPS Next Y. (Est.)
28.58
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.65
Relative Volume
0.41
Return on Equity vs Sector %
-8.6
Return on Equity vs Industry %
12.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
65.4
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading